Exelixis (EXEL) News Today $40.44 +1.30 (+3.32%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$40.72 +0.28 (+0.68%) As of 09/17/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Exelixis Up Today?Toggle Visibility of Why Is Exelixis Up Today?Exelixis, Inc. (NASDAQ:EXEL) shares climbed today amid a flurry of bullish analyst actions, new coverage and a strategic collaboration update. Key drivers include upgraded price targets, fresh buy ratings and an expanded partnership leveraging novel cancer‐therapy technology. Positive Sentiment: Morgan Stanley raised its price target on EXEL to $50 from $46 and maintained an Overweight rating, implying roughly 23.6% upside potential. Exelixis price target raised to $50... Positive Sentiment: Goldman Sachs initiated coverage with a Buy rating and a $47 price target on EXEL, signaling 16.2% upside from current levels. Benzinga coverage Briefing.com report Positive Sentiment: Goldman Sachs analyst Paul Choi flagged strong growth prospects tied to EXEL’s lead candidate Zanzalintinib and initiated a Buy rating. Exelixis: Strong Growth Potential... Positive Sentiment: Adagene amended its collaboration with Exelixis to use SAFEbody technology for next-generation antibody-drug conjugates, unlocking potential milestone payments and royalties. Adagene Inc. Amends Collaboration... Neutral Sentiment: Seventeen analysts weighed in on EXEL with a mix of Buy, Hold and Outperform ratings, alongside varied price targets reflecting both upside and downside scenarios. 17 Analysts Have This To Say... Neutral Sentiment: Barclays assigned an Equal Weight rating with a $40 price target on EXEL, implying a modest 1.1% downside from current levels. Exelixis assumed with an Equal Weight... Negative Sentiment: Wall Street Zen downgraded Exelixis from Buy to Hold, citing valuation concerns and moderating growth visibility. Exelixis Downgraded to "Hold"... Posted 5h agoAI Generated. May Contain Errors. EXEL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Barclays Initiates Coverage of Exelixis (EXEL) with Equal-Weight Recommendation2 hours ago | msn.comExelixis price target raised to $50 from $46 at Morgan StanleySeptember 17 at 7:50 PM | msn.com17 Analysts Have This To Say About ExelixisSeptember 17 at 7:50 PM | benzinga.comExelixis earns new Buy at Goldman Sachs on lead candidateSeptember 17 at 7:50 PM | msn.com32,270 Shares in Exelixis, Inc. $EXEL Acquired by Lifestyle Asset Management Inc.September 17 at 6:01 AM | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Purchases Shares of 111,158 Exelixis, Inc. $EXELSeptember 17 at 5:27 AM | marketbeat.comModern Wealth Management LLC Acquires New Stake in Exelixis, Inc. $EXELSeptember 17 at 3:29 AM | marketbeat.comStrs Ohio Makes New $2.27 Million Investment in Exelixis, Inc. $EXELSeptember 17 at 3:26 AM | marketbeat.comExelixis, Inc. $EXEL Shares Purchased by Voya Investment Management LLCSeptember 17 at 3:26 AM | marketbeat.comExelixis assumed with an Equal Weight at BarclaysSeptember 16 at 11:24 PM | msn.comExelixis initiated with an Equal Weight at BarclaysSeptember 16 at 11:24 PM | msn.comAdagene Inc. Amends Collaboration Agreement with Exelixis to Advance SAFEbody Technology for Cancer TherapySeptember 16 at 8:31 AM | quiverquant.comQLingohr Asset Management GmbH Sells 93,560 Shares of Exelixis, Inc. $EXELSeptember 16 at 5:47 AM | marketbeat.comExelixis (NASDAQ:EXEL) Downgraded to "Hold" Rating by Wall Street ZenSeptember 16 at 2:09 AM | americanbankingnews.comExelixis (NASDAQ:EXEL) Rating Lowered to "Hold" at Wall Street ZenSeptember 16 at 2:05 AM | marketbeat.comBelpointe Asset Management LLC Purchases New Shares in Exelixis, Inc. $EXELSeptember 15 at 3:26 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Receives $44.06 Consensus PT from BrokeragesSeptember 15 at 2:02 AM | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 14, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXELSeptember 13, 2025 | prnewswire.comEllsworth Advisors LLC Buys Shares of 97,208 Exelixis, Inc. $EXELSeptember 13, 2025 | marketbeat.comExelixis, Inc. $EXEL Holdings Decreased by Acadian Asset Management LLCSeptember 13, 2025 | marketbeat.comFortis Capital Advisors LLC Makes New Investment in Exelixis, Inc. $EXELSeptember 13, 2025 | marketbeat.comExelixis, Inc. $EXEL Shares Acquired by Fred Alger Management LLCSeptember 13, 2025 | marketbeat.comExelixis, Inc. $EXEL Stock Holdings Raised by Intech Investment Management LLCSeptember 12, 2025 | marketbeat.com201,609 Shares in Exelixis, Inc. $EXEL Purchased by Capital Impact Advisors LLCSeptember 12, 2025 | marketbeat.comWoodline Partners LP Decreases Stock Position in Exelixis, Inc. $EXELSeptember 12, 2025 | marketbeat.comEmpowered Funds LLC Increases Stake in Exelixis, Inc. $EXELSeptember 12, 2025 | marketbeat.comCaxton Associates LLP Invests $1.24 Million in Exelixis, Inc. $EXELSeptember 12, 2025 | marketbeat.comBayforest Capital Ltd Acquires New Stake in Exelixis, Inc. $EXELSeptember 11, 2025 | marketbeat.comExelixis, Inc. $EXEL Shares Sold by Peloton Wealth StrategistsSeptember 11, 2025 | marketbeat.comPints Of Science Offers Informative, Engaging Lecture Series In TampaSeptember 10, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXELSeptember 10, 2025 | globenewswire.comExelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeptember 10, 2025 | seekingalpha.comKestra Investment Management LLC Has $744,000 Position in Exelixis, Inc. $EXELSeptember 10, 2025 | marketbeat.comExelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comExelixis, Inc. $EXEL Shares Purchased by Royal Bank of CanadaSeptember 9, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Stock Rating Upgraded by Wall Street ZenSeptember 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXELSeptember 8, 2025 | prnewswire.comExelixis, Inc. $EXEL Shares Sold by Jacobs Levy Equity Management Inc.September 8, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Upgraded by Wall Street Zen to "Buy" RatingSeptember 8, 2025 | americanbankingnews.comExelixis Advances Phase 1 Study of XL309 for Advanced Solid TumorsSeptember 7, 2025 | msn.comExelixis Advances in Neuroendocrine Tumor Treatment with New Clinical TrialSeptember 7, 2025 | tipranks.comNFJ Investment Group LLC Purchases 147,471 Shares of Exelixis, Inc. $EXELSeptember 7, 2025 | marketbeat.comNew Vernon Capital Holdings II LLC Acquires Shares of 225,027 Exelixis, Inc. $EXELSeptember 7, 2025 | marketbeat.comGotham Asset Management LLC Raises Stock Position in Exelixis, Inc. $EXELSeptember 7, 2025 | marketbeat.comExelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&DSeptember 7, 2025 | finance.yahoo.com19,207 Shares in Exelixis, Inc. $EXEL Purchased by Focus Partners Advisor Solutions LLCSeptember 7, 2025 | marketbeat.comAlphaQuest LLC Trims Stock Position in Exelixis, Inc. $EXELSeptember 7, 2025 | marketbeat.comExelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&DSeptember 6, 2025 | insidermonkey.comExelixis, Inc. (EXEL): A Bull Case TheorySeptember 5, 2025 | insidermonkey.com Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXEL Media Mentions By Week EXEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼1.280.92▲Average Medical News Sentiment EXEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼3224▲EXEL Articles Average Week Get the Latest News and Ratings for EXEL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Exelixis and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News BioMarin Pharmaceutical News Exact Sciences News Ionis Pharmaceuticals News Madrigal Pharmaceuticals News Halozyme Therapeutics News Repligen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXEL Stock Alerts